Trial Profile

A phase I study of yttrium-90 labeled humanized anti-CEA M5A antibody in patients with CEA producing advanced malignancies.

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti-CEA monoclonal antibody cT84-66-Y-90 (Primary)
Indications Solid tumours
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use

Most Recent Events

27 Feb 2020 Biomarkers information updated
31 Jan 2013 Planned end date changed from 1 Nov 2012 to 1 Nov 2013 as reported by ClinicalTrials.gov.
03 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com